NL0015001WM6 - Common Stock

Taking everything into account, **QGEN** scores **5** out of 10 in our fundamental rating. **QGEN** was compared to 56 industry peers in the **Life Sciences Tools & Services** industry. While **QGEN** has a great profitability rating, there are some minor concerns on its financial health. **QGEN** is valued correctly, but it does not seem to be growing.

In the past year **QGEN** was profitable.

In the past year **QGEN** had a positive cash flow from operations.

Of the past 5 years **QGEN** 4 years were profitable.

With a decent **Return On Equity** value of **2.13%**, **QGEN** is doing good in the industry, outperforming **71.43%** of the companies in the same industry.

The **Average Return On Invested Capital** over the past 3 years for **QGEN** is below the industry average of **11.27%**.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 1.3% | ||

ROE | 2.13% | ||

ROIC | 8.01% |

ROA(3y)6.88%

ROA(5y)5.2%

ROE(3y)12.58%

ROE(5y)9.79%

ROIC(3y)9.15%

ROIC(5y)8.32%

Looking at the **Profit Margin**, with a value of **3.75%**, **QGEN** is in the better half of the industry, outperforming **71.43%** of the companies in the same industry.

In the last couple of years the **Profit Margin** of **QGEN** has grown nicely.

The **Operating Margin** of **QGEN** (**23.18%**) is better than **92.86%** of its industry peers.

In the last couple of years the **Operating Margin** of **QGEN** has grown nicely.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | 23.18% | ||

PM (TTM) | 3.75% | ||

GM | 63.03% |

OM growth 3Y-7.62%

OM growth 5Y3%

PM growth 3Y-3.3%

PM growth 5Y6.5%

GM growth 3Y-1.61%

GM growth 5Y-1.22%

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so **QGEN** is still creating some value.

The number of shares outstanding for **QGEN** has been increased compared to 5 years ago.

An Altman-Z score of **4.06** indicates that **QGEN** is not in any danger for bankruptcy at the moment.

The **Altman-Z score** of **QGEN** (**4.06**) is better than **67.86%** of its industry peers.

The Debt to FCF ratio of **QGEN** is **3.46**, which is a good value as it means it would take **QGEN**, **3.46** years of fcf income to pay off all of its debts.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.27 | ||

Debt/FCF | 3.46 | ||

Altman-Z | 4.06 |

ROIC/WACC1.03

WACC7.75%

A Quick Ratio of **1.46** indicates that **QGEN** should not have too much problems paying its short term obligations.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 1.77 | ||

Quick Ratio | 1.46 |

The earnings per share for **QGEN** have decreased by **-1.71%** in the last year.

EPS 1Y (TTM)-1.71%

EPS 3Y-0.51%

EPS 5Y9.58%

EPS Q2Q%4.61%

Revenue 1Y (TTM)-1.9%

Revenue growth 3Y1.66%

Revenue growth 5Y5.53%

Sales Q2Q%0.3%

The **Revenue** is expected to grow by **6.29%** on average over the next years.

EPS Next Y3.31%

EPS Next 2Y4.94%

EPS Next 3Y6.44%

EPS Next 5Y7.75%

Revenue Next Year0.95%

Revenue Next 2Y3.49%

Revenue Next 3Y4.56%

Revenue Next 5Y6.29%

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.

Based on the **Price/Earnings** ratio of **21.13**, the valuation of **QGEN** can be described as rather expensive.

The average S&P500 **Price/Earnings** ratio is at **31.52**. **QGEN** is valued slightly cheaper when compared to this.

Based on the **Price/Forward Earnings** ratio of **18.85**, the valuation of **QGEN** can be described as rather expensive.

Compared to the rest of the industry, the **Price/Forward Earnings** ratio of **QGEN** indicates a rather cheap valuation: **QGEN** is cheaper than 87.50% of the companies listed in the same industry.

The average S&P500 **Price/Forward Earnings** ratio is at **22.55**. **QGEN** is around the same levels.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 21.13 | ||

Fwd PE | 18.85 |

Based on the **Enterprise Value to EBITDA** ratio, **QGEN** is valued cheaper than 94.64% of the companies in the same industry.

85.71% of the companies in the same industry are more expensive than **QGEN**, based on the **Price/Free Cash Flow** ratio.

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | 24.28 | ||

EV/EBITDA | 15.14 |

The high **PEG Ratio(NY)**, which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.

PEG (NY)6.39

PEG (5Y)2.21

EPS Next 2Y4.94%

EPS Next 3Y6.44%

With a **Yearly Dividend Yield** of **3.00%**, **QGEN** has a reasonable but not impressive dividend return.

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 3% |

Dividend Growth(5Y)N/A

Div Incr Years0

Div Non Decr Years0

DPN/A

EPS Next 2Y4.94%

EPS Next 3Y6.44%

**QIAGEN N.V.**

NYSE:QGEN (10/14/2024, 11:13:21 AM)

**43.95**

**+0.03 (+0.07%) **

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryLife Sciences Tools & Services

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap9.84B

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 3% |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 21.13 | ||

Fwd PE | 18.85 | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)6.39

PEG (5Y)2.21

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 1.3% | ||

ROE | 2.13% | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | 23.18% | ||

PM (TTM) | 3.75% | ||

GM | 63.03% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.35

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.27 | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 1.77 | ||

Quick Ratio | 1.46 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)-1.71%

EPS 3Y-0.51%

EPS 5Y

EPS Q2Q%

EPS Next Y3.31%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-1.9%

Revenue growth 3Y1.66%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y